Merck & Co., Inc. (MRK)
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
Why the Market Dipped But Merck (MRK) Gained Today
Merck (MRK) closed at $79.29 in the latest trading session, marking a +1.29% move from the prior day.
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda.
Here's Why Merck (MRK) Fell More Than Broader Market
In the most recent trading session, Merck (MRK) closed at $80.32, indicating a -1.27% shift from the previous trading day.
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) closed at $81.35 in the latest trading session, marking a +2.55% move from the prior day.
Merck: Best Case For Option Collars We'll Ever See
I use option collars on struggling stocks like Merck & Co., Inc. to cap downside risk while maintaining upside potential, especially when the technicals look uncertain. My MRK collar trade earlier this year limited losses compared to straight ownership, demonstrating why I favor this strategy for "dog" stocks. Currently, MRK stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a new trade yet.
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Company Participants Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M.
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
